All In Biotech

Drug Trial Radar · NCT06691984

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 707 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

707

Actual

Start

Dec 9, 2024

Primary completion

Jan 2, 2029

Study completion Jul 30, 2029

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • XaluritamigDrug

    Short-term IV infusion

  • AbirateroneDrug

    Oral tablets

  • EnzalutamideDrug

    Oral tablets

  • CabazitaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 53 months

Locations

164 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • City of Hope National Medical Center

    Duarte, California

  • Providence Saint Jude Medical Center

    Fullerton, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • University of California San Francisco

    San Francisco, California

  • University of Florida, College of Medicine

    Gainesville, Florida

  • Sylvester Comprehensive Cancer Center-Fox Building

    Miami, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • University of Chicago

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Louisville Health - James Graham Brown Cancer Center

    Louisville, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital, Henry Ford Health Systems

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University

    St Louis, Missouri

  • Yale New Haven Hospital

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University Medical Center Duke Cancer Center

    Durham, North Carolina

  • Sanford Roger Maris Cancer Center

    Fargo, North Dakota

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Sanford Oncology Clinic and Pharmacy

    Sioux Falls, South Dakota

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Intermountain Medical Center

    Murray, Utah

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Swedish Medical Center

    Seattle, Washington

Showing 40 of 164 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.